AZD7760

Phase 1Small molecule

AstraZeneca

AZD7760 is one of 8 small molecule programs targeting Staphylococcus Aureus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Staphylococcus AureusRecruiting

Staphylococcus Aureus Bloodstream InfectionRecruiting

Staphylococcus AureusPreclinical

Recruiting

Staphylococcus Aureus Bloodstream InfectionPhase 1

Recruiting

Competition

Competitive Landscape

9 competitors in Staphylococcus Aureus

#DrugCompanyPhaseTrials

Acanya

Pfizer

Approved

1 2

Vancocin

HHikma Pharmaceuticals LLC

Approved

4 3

Ancef

BBaxter Healthcare Corporation

Approved

2 4

Trimethoprim-Sulfamethoxazole

Astellas

Phase 3

1 5

Duracillin a-S

Sanofi

Phase 3

1 6

Chirocaine

PPurdue Pharma LP

Preclinical

1 7

AZD7760

AstraZeneca

Phase 1

1 8

Neosporin

NNorthwestern University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Staphylococcus Aureus Bloodstream Infection

NCT07612813

Q1 2028

PreclinicalRecruiting

Staphylococcus Aureus

NCT06749457

Clinical

Trials by Indication[1]

Staphylococcus Aureus Bloodstream Infection1 trial

A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Japanese Adult Participants

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT07612813·18 enrolled

Staphylococcus Aureus1 trial

A Phase I/IIa Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Participants and in Patients With End-stage Kidney Disease Receiving Hemodialysis Through a Central Venous Catheter

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT06749457·231 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AZD7760. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD7760 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD7760. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AstraZeneca

AZD7760

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q1 2028

Trials by Indication[1]

Staphylococcus Aureus Bloodstream Infection1 trial

Staphylococcus Aureus1 trial

References

Drug Info

Quick Facts

Related News